Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib
نویسندگان
چکیده
منابع مشابه
Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant
Patients with chronic lymphocytic leukemia (CLL) who progress to Richter transformation (RT) have a poor prognosis. Multi-agent chemotherapy regimens do not have good response rates. There are few case reports on the use of ibrutinib in RT. Here, we present a patient who was heavily pretreated for CLL, including allogeneic stem cell transplant, and progressed to RT. She had a mixed response to ...
متن کاملRichter syndrome: chronic lymphocytic leukemia transformation into Hodgkin's disease.
r ichter syndrome is a clinical condition in which indolent chronic lymphocytic leukemia evolves into a more aggressive diffuse large B cell lymphoma. Maurice Nethaniel Richter first described this phenomenon in 1928, which was named the “Richter syndrome” in 1964 [1]. Due to the aggressive nature of the disorder, the clinical manifestations, prognosis and treatment differ from CLL1 [2]. Sympto...
متن کاملGenetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome
Richter syndrome (RS) derives from the rare transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, most commonly of the diffuse large B cell lymphoma (DLBCL) type. The molecular pathogenesis of RS is only partially understood. By combining whole-exome sequencing and copy-number analysis of 9 CLL-RS pairs and of an extended panel of 43 RS cases, we show that this aggre...
متن کاملRash Associated with Ibrutinib Therapy for Chronic Lymphocytic Leukemia
Ibrutinib is used in the treatment of chronic myeloid leukemia. While patients taking the drug have developed rashes, there are few case reports and studies documenting this adverse effect. We present a case of rash associated with Ibrutinib therapy in a patient with chronic lymphocytic leukemia.
متن کاملOutcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of patients with relapsed refractory chronic lymphocytic leukemia (RR-CLL). We describe the characteristics, causes of discontinuation, and outcomes in patients who discontinued treatment with ibrutinib. One hundred twenty-seven patients were enrolled in various clinical trials of ibrutinib, with or without rituximab, at...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood Advances
سال: 2017
ISSN: 2473-9529,2473-9537
DOI: 10.1182/bloodadvances.2017007302